专利号:US-8734846-B2 优先权日:2008-06-16 标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles 发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS 权利人:BIND BIOSCIENCES INC 摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.
专利号:US-2007160574-A1 优先权日:2000-04-12 标题 :Design of CXC chemokine analogs for the treatment of human diseases 发明人:MERZOUK AHMED; SALARI HASSAN 权利人:MERZOUK AHMED; SALARI HASSAN 摘要:The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.
专利号:WO-2007079460-A3 优先权日:2006-01-04 标题:Design of cxc chemokine analogs for the treatment of human diseases 发明人:MERZOUK AHMED; SALARI HASSAN 权利人:CHEMOKINE THERAPEUTICS CORP; MERZOUK AHMED; SALARI HASSAN 摘要:The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.
专利号:US-2014315720-A1 优先权日:2012-10-24 标 题 :Polysaccharide ester microspheres and methods and articles relating thereto 发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY 权利人:CELANESE ACETATE LLC 摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
专利号:US-2012232031-A1 优先权日:2009-10-19 标 题:Injectable formulations for intra-articular or peri-articular administration 发明人:HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE 权利人:HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE; PANMIRA PHARMACEUTICALS LLC 摘要:Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.
1: Tatsushima Y, Egashira N, Matsushita N, Kurobe K, Kawashiri T, Yano T, Oishi R. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. doi: 10.1016/j.ejphar.2011.04.026. Epub 2011 Apr 27. doi: 10.1055/s-0031-1296461. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther. 2002 Oct;18(5):475-88. Japanese. Japanese. Japanese.
合成参考文献
摘要:Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 3038 摘要: 参考文献:10.1159/000237363 摘要:Minoda R, Masuyama K, Toriya T, Uno K, Eura M, Ishikawa T. Recurrent hearing impairment and nystagmus induced by repeated antigen exposure in actively sensitized guinea pigs. Int Arch Allergy Immunol. 1996 Oct;111(2):166–72. doi: 10.1159/000237363. 参考文献:10.1055/s-0031-1296461 摘要:Gohda T, Ra C, Hamada C, Tsuge T, Kawachi H, Tomino Y. Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittelforschung. 2008;58(1):18–23. doi: 10.1055/s-0031-1296461.